21 May 2013
Keywords: serono, ready, acquisition, trial, turns, first-quarter, profit
Article | 01 May 2006
Europe's leading biotechnology company Serono, which has just taken itself off the selling-block, is now keen to make acquisitions instead.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 May 2006
20 May 2013
© 2013 thepharmaletter.com